Patents by Inventor Francois Bilodeau
Francois Bilodeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9315499Abstract: Compounds of Formula (I) wherein n, m, R1, R2, R3, R4, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.Type: GrantFiled: April 3, 2013Date of Patent: April 19, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Lee Fader, Olivier Lepage, Murray Bailey, Pierre Louis Beaulieu, Francois Bilodeau, Rebekah J. Carson, André Giroux, Cédrickx Godbout, Benoît Moreau, Julie Naud, Mathieu Parisien, Martin Poirier, Maude Poirier, Simon Surprenant, Carl Thibeault
-
Patent number: 9284310Abstract: Compounds of Formula (I) wherein n, R1, R1A, R2, R3, Y and Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.Type: GrantFiled: October 31, 2013Date of Patent: March 15, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Lee Fader, Francois Bilodeau, Mathieu Parisien, Maude Poirier, Cyrille Kuhn, Carl Thibeault, Thao Trinh
-
Patent number: 9249158Abstract: Compounds of Formula (I) wherein n, A, R1, R2, R3 and R5 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.Type: GrantFiled: April 3, 2013Date of Patent: February 2, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Lee Fader, Pierre Louis Beaulieu, Murray Bailey, Francois Bilodeau, Rebekah J. Carson, André Giroux, Cédrickx Godbout, Oliver Hucke, Marc-André Joly, Mélissa Leblanc, Olivier Lepage, Benoit Moreau, Julie Naud, Martin Poirier, Elisia Villemure
-
Publication number: 20150315180Abstract: Compounds of Formula (I) wherein n, R1, R1A, R2, R3, Y and Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.Type: ApplicationFiled: October 31, 2013Publication date: November 5, 2015Applicant: Boehringer Ingelheim International GmbHInventors: Lee FADER, Francois BILODEAU, Mathieu PARISIEN, Maude POIRIER, Cyrille KUHN, Carl THIBEAULT, Thao TRINH
-
Publication number: 20150158861Abstract: Compounds of Formula (I) wherein n, m, R1, R2, R3, R4, R5 and R6 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.Type: ApplicationFiled: April 3, 2013Publication date: June 11, 2015Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Lee Fader, Olivier Lepage, Murray Bailey, Pierre Louis Beaulieu, Francois Bilodeau, Rebekah J. Carson, André Giroux, Cédrickx Godbout, Benoît Moreau, Julie Naud, Mathieu Parisien, Martin Poirier, Maude Poirier, Simon Surprenant, Carl Thibeault
-
Publication number: 20150080366Abstract: Compounds of Formula (I) wherein n, A, R1, R2, R3 and R5 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.Type: ApplicationFiled: April 3, 2013Publication date: March 19, 2015Applicant: Boehringer Ingelheim International GmbHInventors: Lee Fader, Pierre Louis Beaulieu, Murray Bailey, Francois Bilodeau, Rebekah J. Carson, André Giroux, Cédrickx Godbout, Oliver Hucke, Marc-André Joly, Mélissa Leblanc, Olivier Lepage, Benoit Moreau, Julie Naud, Martin Poirier, Elisia Villemure
-
Publication number: 20140296228Abstract: Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.Type: ApplicationFiled: February 28, 2014Publication date: October 2, 2014Applicant: Gilead Sciences, Inc.Inventors: Youla S. Tsantrizos, Murray D. Bailey, Francois Bilodeau, Rene Coulombe, Teddy Halmos, Stephen Kawai, Serge R. Landry, Steven LaPlante, Sebastien Morin, Marc-Andre Poupart, Bruno Simoneau, Lee Fader, Rebekah J. Carson, Mathieu Parisien
-
Patent number: 8841331Abstract: Compounds of formula I: wherein a, R1, R2, R3, R4, R5 and R6 are defined herein, are useful as inhibitors of HIV replication.Type: GrantFiled: November 21, 2012Date of Patent: September 23, 2014Assignee: Gilead Sciences, Inc.Inventors: Christiane Yoakim, Murray D. Bailey, Francois Bilodeau, Rebekah Carson, Lee Fader, Stephen Kawai, Sebastien Morin, Carl Thibeault, Bruno Simoneau, Simon Surprenant, Youla S. Tsantrizos, Steven R. Laplante
-
Patent number: 8710230Abstract: Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.Type: GrantFiled: November 21, 2012Date of Patent: April 29, 2014Assignee: Gilead Sciences, Inc.Inventors: Youla S. Tsantrizos, Murray D. Bailey, Francois Bilodeau, Rene Coulombe, Teddy Halmos, Stephen Kawai, Serge R. Landry, Steven LaPlante, Sebastien Morin, Marc-Andre Poupart, Bruno Simoneau, Lee Fader, Rebekah J. Carson, Mathieu Parisien
-
Patent number: 8354429Abstract: Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.Type: GrantFiled: September 11, 2008Date of Patent: January 15, 2013Assignee: Gilead Sciences, Inc.Inventors: Youla S. Tsantrizos, Murray D. Bailey, Francois Bilodeau, Rebekah J. Carson, Rene Coulombe, Lee Fader, Teddy Halmos, Stephen Kawai, Serge Landry, Steven LaPlante, Sebastien Morin, Mathieu Parisien, Marc-Andre Poupart, Bruno Simoneau
-
Patent number: 8338441Abstract: Compounds of formula I: wherein a, R1, R2, R3, R4, R5 and R6 are defined herein, are useful as inhibitors of HIV replication.Type: GrantFiled: May 11, 2010Date of Patent: December 25, 2012Assignee: Gilead Sciences, Inc.Inventors: Christiane Yoakim, Murray Bailey, Francois Bilodeau, Rebekah Carson, Lee Fader, Stephen Kawai, Sebastien Morin, Carl Thibeault, Bruno Simoneau, Simon Surprenant, Youla Tsantrizos, Steven Laplante
-
Publication number: 20100311735Abstract: Compounds of formula I: wherein R4, R6 and R7 are defined herein, are useful as inhibitors of HIV replication.Type: ApplicationFiled: September 11, 2008Publication date: December 9, 2010Applicant: BOEHRINGER INGLEHEIM INTERNATIONAL GMBHInventors: Youla S. Tsantrizos, Murray D. Bailey, Francois Bilodeau, Rene Coulombe, Teddy Halmos, Stephen Kawai, Serge R. Landry, Steven LaPlante, Sebastien Morin, Marc-Andre Poupart, Bruno Simoneau, Lee Fader, Rebekah J. Carson, Mathieu Parisien
-
Publication number: 20100292227Abstract: Compounds of formula I: wherein a, R1, R2, R3, R4, R5 and R6 are defined herein, are useful as inhibitors of HIV replication.Type: ApplicationFiled: May 11, 2010Publication date: November 18, 2010Applicant: BOEHRINGER INGLEHEIM INTERNATIONAL GMBHInventors: CHRISTIANE YOAKIM, MURRAY BAILEY, FRANCOIS BILODEAU, REBEKAH CARSON, LEE FADER, STEPHEN KAWAI, SEBASTIEN MORIN, CARL THIBEAULT, BRUNO SIMONEAU, SIMON SURPRENANT, YOULA TSANTRIZOS, STEVEN LAPLANTE
-
Patent number: 7749961Abstract: Compounds of formula (I): wherein R1, R2, X, R3, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.Type: GrantFiled: January 19, 2005Date of Patent: July 6, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Bailey, Punit K. Bhardwaj, Francois Bilodeau, Pasquale Forgione, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Jean Rancourt
-
Publication number: 20100087382Abstract: Compounds of formula I: wherein R1, R2, R2a, R3, R4 and R5 are defined herein, are useful as inhibitors of the HCV NS3 protease.Type: ApplicationFiled: February 15, 2008Publication date: April 8, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Murray D. Bailey, Francois Bilodeau, Pasquale Forgione, Vida Gorys, Montse Llinas-Brunet, Julie Naud, Jeffrey O'Meara, Marc-Andre Poupart
-
Publication number: 20090264346Abstract: Compounds of formula (I): wherein R1, R2, X, R3, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.Type: ApplicationFiled: June 29, 2009Publication date: October 22, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Montse LLINAS-BRUNET, Murray BAILEY, Francois BILODEAU, Pasquale FORGIONE, Elise GHIRO, Nathalie GOUDREAU, Teddy HALMOS, Jean RANCOURT
-
Patent number: 7606452Abstract: A device for providing an expanded mode field from a single mode optical waveguide is formed by fusing a length of single mode optical fiber with a length of fiber rod absent a cladding and adiabatically tapering the fused region. The length of single mode fiber has a core having a refractive index nco and a cladding having a refractive index ncl, wherein ncl<nco and wherein the cladding has an outer diameter ?. The length of fiber rod absent the cladding has a refractive index of the fiber rod is substantially the same as the cladding index ncl of the single mode optical fiber. The outer diameter of the length of fiber rod is ?, the same as the cladding diameter of the single mode fiber.Type: GrantFiled: August 13, 2008Date of Patent: October 20, 2009Assignee: Her Majesty the Queen in Right of Canada, as represented by the Minister of Industry, through the Communications Research Centre CanadaInventors: Francois Bilodeau, Bernard Malo, Stephen Mihailov
-
Publication number: 20090060417Abstract: A device for providing an expanded mode field from a single mode optical waveguide is formed by fusing a length of single mode optical fiber with a length of fiber rod absent a cladding and adiabatically tapering the fused region. The length of single mode fiber has a core having a refractive index nco and a cladding having a refractive index ncl, wherein ncl<nco and wherein the cladding has an outer diameter ?. The length of fiber rod absent the cladding has a refractive index of the fiber rod is substantially the same as the cladding index ncl of the single mode optical fiber. The outer diameter of the length of fiber rod is ?, the same as the cladding diameter of the single mode fiber.Type: ApplicationFiled: August 13, 2008Publication date: March 5, 2009Inventors: Francois Bilodeau, Bernard Malo, Stephen Mihailov
-
Publication number: 20050192212Abstract: Compounds of formula (I): wherein R1, R2, X, R3, D, and the dotted line b are as defined herein; or a pharmaceutically acceptable salt or ester thereof, are useful as inhibitors of the HCV NS3 protease.Type: ApplicationFiled: January 19, 2005Publication date: September 1, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Montse Llinas-Brunet, Murray Bailey, Punit Bhardwaj, Francois Bilodeau, Pasquale Forgione, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Jean Rancourt
-
Patent number: 6374016Abstract: A method is disclosed wherein optical structures such as Bragg gratings can be written into planar waveguides disposed on a substrate. By employing the method of this invention, a polarization insensitive device can be made. Such relatively thin planar waveguides disposed on a substrate are inherently polarization sensitive and the structure itself is birefringent. By writing structures in the waveguides or by simply writing a refractive index change in the waveguide by limiting the beam width at the waveguide layer to less than or equal to the thickness of the waveguiding layers on the substrate, in combination with conventional wider beam writing techniques, polarization sensitivity can be lessened or obviated.Type: GrantFiled: April 6, 2001Date of Patent: April 16, 2002Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of IndustryInventors: Jacques Albert, Francois Bilodeau, Kenneth O. Hill, Derwyn C. Johnson, Stephen J. Mihailov
